Evoke Pharma, Inc., a specialty pharmaceutical company, is focused on the development of drugs that treat GI disorders and diseases. The company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent gastroparesis in women with diabetes mellitus. With diabetic gastroparesis, the stomach takes too long to empty its contents resulting in serious digestive system symptoms. Metoclopramide is the only product currently approved in the United States to treat gastroparesis but it is only available in oral and intravenous forms. EVK-001 is a novel formulation of this drug, designed to provide systemic delivery of metoclopramide through intranasal administration. For more information, visit the company’s website at www.evokepharma.com.